MCK - McKesson Corporation
| Previous Close | 127.09 |
| Open | 126.82 |
| Bid | 120.34 x 1200 |
| Ask | 132.00 x 800 |
| Day's Range | 126.74 - 130.58 |
| 52 Week Range | 122.63 - 178.86 |
| Volume | 1,814,243 |
| Avg. Volume | 1,771,629 |
| Market Cap | 25.846B |
| Beta | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | 1.56 (1.26%) |
| Ex-Dividend Date | 2018-08-31 |
| 1y Target Est | 151.00 |
- Zacks•10 days ago
Allscripts Gains From Strong Results in Q2, Competition Rife
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
Markit•10 days agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
Markit•11 days agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
- Business Wire•18 days ago
McKesson Appoints Brian Tyler as President and Chief Operating Officer
McKesson Corporation (MCK) today announced that Brian S. Tyler, Ph.D., has been appointed president and chief operating officer, McKesson Corporation, effective August 2, 2018. Tyler will report to John Hammergren, chairman and chief executive officer, and will become a member of the executive committee. “Brian is ideally suited to lead McKesson’s global operations based on his deep industry knowledge, outstanding track record as a business leader, and his commitment to operational excellence and customer success,” said Hammergren.
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of MCK earnings conference call or presentation 26-Jul-18 12:00pm GMT
Q1 2019 McKesson Corp Earnings Call
- Bloomberg•22 days ago
McKesson Sales Growth at Risk as Drugmakers Curb Price Increases
Drugmakers are tapping the brakes on price increases. For McKesson Corp. investors, that could mean lost sales.
- Bloomberg•22 days ago
McKesson Growth at Risk as Drugmakers Curb Price Increases
Drugmakers are tapping the brakes on price increases. For McKesson Corp. investors, that could mean lost sales. If pharmaceutical companies continue to put off plans to raise prices amid pressure from the Trump administration, that could threaten San Francisco-based McKesson’s bottom line.
- Zacks•22 days ago
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
- Motley Fool•22 days ago
McKesson Corporation Helped by U.S. Tax Cuts, Hurt by U.K. Reimbursement Cuts
The drug distributor's adjusted profits soared thanks to U.S. corporate tax reform, but it faces even more challenges in Europe.
- MarketWatch•23 days ago
McKesson shares drop 3% after Q1 revenue miss
MARKET PULSE McKesson Corp. (MCK) shares dropped 3.2% in moderate Thursday morning trade after the drug distributor reported a first-quarter revenue miss. Earnings for the latest quarter came to a loss of $138 million, or a loss of 68 cents per share, after earnings of $309 million, or $1.
- Zacks•23 days ago
McKesson's (MCK) Q1 Earnings Beat Estimates, Sales Improve Y/Y
McKesson???s Q1 results were driven by solid performance in Medical-Surgical Solutions segment.
- Zacks•23 days ago
McKesson (MCK) Q1 Earnings Top Estimates
McKesson (MCK) delivered earnings and revenue surprises of 0.35% and -0.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•23 days ago
McKesson: Fiscal 1Q Earnings Snapshot
The San Francisco-based company said it had a loss of 68 cents per share. Earnings, adjusted for one-time gains and costs, were $2.90 per share. The results beat Wall Street expectations. The average estimate ...
- Business Wire•23 days ago
McKesson Reports Fiscal 2019 First-Quarter Results
SAN FRANCISCO-- -- Revenues of $52.6 billion for the first quarter, up 3% year over year. First-quarter GAAP loss per diluted share from continuing operations of $ . First-quarter Adjusted Earnings per diluted share of $2.90, up 18% year over year. Fiscal 2019 Outlook: Adjusted Earnings of $13.00 to $13.80 per diluted share. Board of Directors approved raising the quarterly dividend by 15% from 34 ...
Yahoo Finance•23 days agoFacebook crashes, Amazon reports earnings — What you need to know in markets on Thursday
Facebook's post-earnings collapse after hours on Wednesday will set the tone for markets on Thursday, though investors shook off poor results from Netflix earlier this month.
- Business Wire•23 days ago
McKesson Announces Preliminary Voting Results from 2018 Annual Meeting of Stockholders
McKesson Corporation (MCK) today announced preliminary voting results from its Annual Meeting of Stockholders, held earlier today in Irving, Texas. All directors were re-elected, the non-binding advisory vote on executive compensation was approved, and all Board vote recommendations were supported. “On behalf of our Board and management team, we appreciate the continued support of our shareholders,” said John H. Hammergren, chairman and chief executive officer, McKesson Corporation.
- Reuters•24 days ago
Pharma's middlemen see shares suffer as challenges grow
Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent. Six S&P 500 stocks - CVS Health Corp, Walgreens Boots Alliance Inc, AmerisourceBergen Corp, McKesson Corp, Cardinal Health Inc and Express Scripts Holding Co - collectively recently traded a third below their average valuation of the past five years, based on price-to-earnings estimates, according to Thomson Reuters Datastream. Fears the U.S. government will take actions to rein in prescription drug prices, an issue trumpeted by U.S. President Donald Trump, have cast a cloud over the stocks.
- Zacks•24 days ago
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Markit•28 days agoSee what the IHS Markit Score report has to say about McKesson Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MCK. Over the last one-month, outflows of investor capital in ETFs holding MCK totaled $833 million.
- InvestorPlace•last month
New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
- American City Business Journals•last month
Sure, these corporate workforces make the big bucks, but do they deserve it?
Who has the most productive workforce in the Bay Area, and how much does each employee rake in per year, on average?
- American City Business Journals•last month
Here's how much CoverMyMeds would pay – and save – after tax breaks for HQ project
The proposed CoverMyMeds headquarters would save as much as $83 million over 15 years if Columbus City Council approves two incentive packages toward the $240 million project. Here's how much net new taxes would be generated over that time and beyond.
Associated Press•last monthSan Francisco to consider tax on companies to help homeless
SAN FRANCISCO (AP) — San Francisco voters will decide in November whether to tax large businesses to pay for homeless and housing services, an issue that set off a battle in another West Coast city struggling with income inequality.
- CNBC Videos•23 days ago
Can McKesson turn a corner? Plus, the trade on CSX
The "Halftime Report" traders answer viewer questions on McKesson and CSX.
